MA-PERKINELMER
26.10.2020 13:02:12 CET | Business Wire | Press release
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review by the U.S. FDA for Emergency Use Authorization (EUA). The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus (RSV) in a single test, which will be critical to manage the surge in test demand during the flu season as the targeted pathogens have some similar signs and symptoms.
Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample collected from individuals suspected of respiratory viral infection consistent with COVID-19, the flu and RSV. Building off the most sensitive SARS-CoV-2 test kit in the market according to the FDA’s reference panel comparative data, the multi-analyte panel is designed to be used with PerkinElmer’s automated viral nucleic extractor to detect smaller amounts of viral material in samples.
“In the next few months, it will be vital for health professionals to detect and differentiate between COVID-19, the common flu and RSV infection,” said Masoud Toloue, Ph.D., Vice President and General Manager, Diagnostics, PerkinElmer. “By offering an automated multi-analyte testing solution, we are equipping diagnostics labs with the right toolset to tackle the additional pressure the season may have on this pandemic.”
PerkinElmer continues to work with specialty and reference diagnostic labs, clinics, hospitals, pharmaceutical and biopharmaceutical labs, academia, and governmental and research institutes to battle the pandemic. PerkinElmer’s comprehensive SARS-CoV-2 offerings span high throughput RNA extraction , RT-PCR , automation , ELISA , chemiluminescence , time-resolved fluorescence and lateral flow based serology testing .
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005308/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Secures 450 MW Order to Power Next-Generation Data Centers17.9.2026 14:30:00 CEST | Press release
U.S. based energy company orders Jenbacher J624 containerized engines to support deployment of fast-track, behind-the-meter power solutions for large-scale data centers 450 MW firm order booked in Q3 2026 INNIO N.V. (Nasdaq: INIO) today announced it has secured an order from a U.S. energy company for 450 megawatts (MW) of power infrastructure. INNIO's Jenbacher J624 containerized gas engines will support the deployment of prime power solutions for large-scale data center projects in North America. The order reflects continued demand for the company's high-efficiency gas engine technology as data center developers seek off-grid alternatives to constrained grid infrastructure. This is the first order by the customer of this scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917646026/en/ INNIO secures 450 MW order to power next-generation data centers The engines are expected to be delivered by 2028. The firm order was b
Adtran showcases open optical networking for AI infrastructure at OIF’s ECOC 2026 interop demo17.9.2026 14:00:00 CEST | Press release
News summary: Open optical ecosystems give operators greater flexibility and vendor choice as they scale networks for the AI era Adtran’s pluggable coherent ZR+ transceivers, FSP 3000 OLS and Mosaic Network Controller key to open transport and hierarchical control in OIF demo Adtran also hosted the OIF test run in its system integration labs in Gdynia, Poland, helping to ensure the demo’s success at the show Adtran today announced its participation in OIF’s live multi-vendor interoperability demo at ECOC 2026, taking place September 21 to 23 in Málaga, Spain. Bringing together 39 member companies, the showcase highlights interoperable optical transport, pluggable coherent transceivers and network control technologies in a multi-vendor environment. Adtran is contributing 100Gbit/s, 400Gbit/s and 800Gbit/s ZR+ pluggables, its FSP 3000 open line system (OLS) operating across C- and L-bands and Mosaic Network Controller software. Ahead of the event, Adtran also hosted the OIF test run in G
IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed17.9.2026 13:00:00 CEST | Press release
New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916599752/en/ IFF has launched Omni-Bos™ PHY, a phytase enzyme developed specifically for dairy cattle, that helps producers unlock nutrients already present in feed to improve nutrient utilization and feed efficiency. “We believe the future of dairy nutrition is helping cows receive m
EdgeConneX Appoints SVP of Global Construction Delivery, Vice Presidents for Norway and Germany17.9.2026 13:00:00 CEST | Press release
New leaders to drive customer delivery and success, market development and growth, and community engagement EdgeConneX®, a global leader in Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced the appointments of Garry O’Leary as SVP, Delivery, Global, Anders Hilt as Vice President of Norway, and Michael Barth as Vice President of Germany. All three hires bring a deep commitment to building strong local relationships and will play a key role in advancing the company's global projects and supporting community engagement and local support efforts. EdgeConneX continues to expand its platform globally, with gigawatts of major projects underway across multiple continents. As SVP, Delivery, Global, Garry plays a critical role in delivering the company's new capacity on time and on budget, overseeing regional construction leadership, contractor and vendor management, site safety, quality assurance, and supply chain. Prior to joining EdgeConneX, Garry was Vice P
Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right17.9.2026 12:40:00 CEST | Press release
Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life. Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911054017/en/ Oral-B iO9 makes a superior clean easier to achieve every day. Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom